Clinical Study

Multicenter Experience with Nonischemic Multiport Laparoscopic and Laparoendoscopic Single-Site Partial Nephrectomy Utilizing Bipolar Radiofrequency Ablation Coagulator

Wassim M. Bazzi,1 Mohamad E. Allaì,2 Jared Berkowitz,2 Hany N. Atalah,3 Sijo Parekattil,3 and Ithaar H. Derweesh1,4

1 Division of Urology, Department of Surgery, University of California San Diego School of Medicine, San Diego, CA 92103, USA
2 James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
3 Department of Urology, University of Florida College of Medicine, Gainesville, FL 32610, USA
4 Division of Urologic Oncology, Moores UCSD Cancer Center, 3855 Health Sciences Drive, 0987 La Jolla, CA 92093, USA

Correspondence should be addressed to Ithaar H. Derweesh, iderweesh@ucsd.edu

Received 29 January 2011; Accepted 14 April 2011

Academic Editor: Kazuo Inui

Copyright © 2011 Wassim M. Bazzi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate feasibility of multiport and laparoendoscopic single-site (LESS) nonischemic laparoscopic partial nephrectomy (NI-LPN) utilizing bipolar radiofrequency coagulator. Methods. Multicenter retrospective review of 60 patients (46 multiport/14 LESS) undergoing NI-LPN between 4/2006 and 9/2009. Multiport and LESS NI-LPN utilized Habib 4X bipolar radiofrequency coagulator to form a hemostatic zone followed by nonischemic tumor excision and renorrhaphy. Demographics, tumor/perioperative characteristics, and outcomes were analyzed. Results. 59/60 (98.3%) successfully underwent NI-LPN. Mean tumor size was 2.35 cm. Mean operative time was 160.0 minutes. Mean estimated blood loss was 131.4 mL. Preoperative/postoperative creatinine (mg/dL) was 1.02/1.07 (P = .471). All had negative margins. 12 (20%) patients developed complications. 3 (5%) developed urine leaks. No differences between multiport and LESS-PN were noted as regards demographics, tumor size, outcomes, and complications. Conclusion. Initial experience demonstrates that nonischemic multiport and LESS-PN is safe and efficacious, with excellent short-term preservation of renal function. Long-term data are needed to confirm oncological efficacy.

1. Introduction

In 2009, there were approximately 57,760 new cases of kidney cancer with 12,980 deaths in the United States [1]. Increasing incidence of small renal masses (SRMs) [2], along with an increased awareness of the metabolic consequences of removal of normally functioning renal tissue by radical nephrectomy [3–7], has led to a paradigm shift of surgical management with greater emphasis on nephron sparing and minimally invasive approaches [8, 9]. While laparoscopic partial nephrectomy (LPN) is becoming recognized as a standard for management of SRM, concerns regarding prolonged warm ischemia times continue to forestall its widespread adoption [8, 9].

By combining working trocar sites and the eventual extraction site into a single location, laparoendoscopic single-site (LESS) surgery further limits the invasiveness of laparoscopy and may enhance advantages associated with traditional laparoscopy. Reduced incisional morbidity and improved cosmesis have largely sparked a growing interest in the utilization of this technique to perform upper tract urologic surgery [10–13]. Recent reports have demonstrated the feasibility of LESS partial nephrectomy [12, 13].

The Habib 4X (Angiodynamics, Queensbury, NY) is a bipolar radiofrequency coagulation device which has been used for nonischemic resections of the liver [14] as well as kidney [15]. We investigated the feasibility, efficacy, and renal
2. Patients and Methods

Multicenter retrospective review of 60 patients (31M/29F, mean age of 57.9 years) who underwent nonischemic (NI-) LPN between 4/2006 and 9/2009. Mean followup was 16.3 ± 10.5 months. Institutions (performing surgeons) were as follows: University of California San Diego (IHD), Johns Hopkins University (MEA), and University of Florida (SP). Selection criteria were patients with contrast-enhancing small renal masses that would be technically amenable for multiport or LESS partial nephrectomy (PN).

2.1. Surgical Technique Multiport LPN. All procedures were performed by transperitoneal laparoscopic or retroperitoneoscopic approaches [16]. Briefly, after obtaining transperitoneal or retroperitoneoscopic access, the kidney was mobilized following ureteral identification. Hilar control was obtained, and the vessels were prepared for possible ischemic occlusion if the need arose. The kidney was then defatted to expose the tumor or region of the tumor. The tumor was circumscribed with at least a 1.0 cm margin utilizing the Habib 4X (Figure 1) to create a zone of hemostasis (Figure 2(a)). The Habib 4X utilizes the RITA 1500X generator which operates at 480 KHz with a 125 W power that has 4 tines (3 cm in length and 1 cm apart) with 2 planes of coagulation created by each 2 tines. The depth of coagulation is controlled by the depth of insertion, and the duration of coagulation is controlled by the surgeon with on-demand repeat. The duration is gradually decreased because of the rise in tissue impedance from charring. We typically use a 50 W setting but that is usually dropped to 25 W for larger vessels to allow for longer duration of coagulation. Parenchymal bleeding is encountered when the tines are removed and that is controlled by reinsertion over the site of bleeding.

After the tumor is clearly demarcated by a zone of coagulation, it is excised by cold EndoShears (Covidien, Mansfield, Mass) (Figure 2(b)). Standard sutured renorrhaphy (Figure 2(c)) was then performed with sutured collecting system closure, and FloSeal (Baxter, Deerfield, Ill) was utilized as a hemostatic adjunct, and the parenchymal defect was closed over an oxidized cellulose mesh bolster with interrupted sutures using LapraTy absorbable clips (Ethicon, Cincinnati, Ohio) [17] (Figure 2(d)). Specimens were intraoperatively evaluated by a pathologist for margin status (Figure 3). A Jackson-Pratt drain was placed to monitor for delayed bleed or leaks.

2.2. Surgical Technique for Nonischemic LESS-PN. After general anesthesia, the patient is placed in a modified flank position (with the patient at a 30-degree angle with the kidney rest up and the table flexed). A 3-4 cm periumbilical incision is made and carried down to the anterior abdominal wall fascia. A 5 mm extra long (150 mm length) Xcel trocar (Ethicon-Endosurgery, Cincinnati, Ohio) is then inserted at the most cranial aspect of this incision, at the junction of the umbilicus with the fascia; pneumoperitoneum to 15 mmHg is obtained, and a 5 mm zero-degree 35 cm long laparoscope (Strkyer, Kalamazoo, Mich) is inserted to inspect the abdomen; subsequently, a 65 mm long, nonshielded low profile (65 mm length) trocar (Ethicon) is inserted under direct vision at a position of 1.0–1.5 cm caudal to the initial port, followed by the insertion of a standard length (100 mm) 12 mm Xcel trocar (Ethicon) at the most caudal aspect of the incision; another 1.0–1.5 cm caudal to the prior low profile port. We minimized the intracorporeal profile of the Xcel trocars, and that in conjunction with the variety of trocar lengths allowed us to stagger the external profiles in order to minimize instrument clashing (Figure 4).

Tissue dissection is largely performed with standard extra long laparoscopic instruments (nonlocking laparoscopic deBakey bowel forceps, right angle dissector, Maryland dissectors) and 5 mm harmonic ACE 36 cm curved shears (Ethicon). Utilization of extra-long instruments creates extracorporeal triangulation which compensates for the intracorporeal triangulation afforded by spaced trocars in multisite laparoscopy. Following the takedown of the white line of Toldt, the 0-degree laparoscope is exchanged for a 5 mm, 45 cm, 30-degree laparoscope with a right angle adaptor and inline camera head (Strkyer).

Initial surgical steps including colonic mobilization, ureteral identification, and vascular dissection are identical to multiport LPN. The standard techniques of LPN are recapitulated with few modifications [16]. The Habib 4X then was utilized to achieve a zone of parenchymal hemostasis in the absence of ischemic renal conditions prior to cold tumor excision and renorrhaphy, as described above [15–17].

2.3. Postoperative Protocol. It consisted of first night bed rest, then rapid mobilization, and advancement of diet as tolerated with monitoring of renal function, urine, and drain outputs. If no evidence of a leak was noted, the drain and Foley were discontinued prior to discharge. Outpatient followup consisted of serial physical exams, serum chemistries and hematologic labs, and radiographic surveillance.

2.4. Data Analysis. We analyzed patient demographics (age, gender, BMI, and race), operative outcomes (operative time, estimated blood loss, and collecting system entry), pathologic outcomes (size, margin status, and final pathology),
Diagnostic and Therapeutic Endoscopy

Figure 2: (a) Laparoscopic Habib 4X circumscribing left kidney lower pole tumor; (b) nonischemic cold excision of renal tumor; (c) sutured renorrhaphy; and (d) FloSeal application for hemostasis.

Figure 3: Resected left lower pole inked margin demonstrated by intraoperative pathology consult.

and complications (urologic and nonurologic). TNM stage was defined by the American Joint Committee on Cancer 2002 [18]. Renal function was determined by serum creatinine (mg/dL) measurement and calculated estimated glomerular filtration rate (eGFR) using the MDRD formula (eGFR (in mL per minute per 1.73 m²) = 186 × sCr − 1.154 × age°.203 × (0.742 if female) × (1.210 if black)) [19]. Means were compared between the two groups (multiport and LESS) using t-tests/ANOVA and fisher’s exact test for continuous and categorical variables, respectively. All reported P values were based on two-sided tests of significance, with P < .05 considered to indicate statistical significance.

3. Results

59/60 (98.3%) patients successfully underwent nonischemic LPN and LESS-PN. One patient, an attempted LESS-PN on a patient with a posterior left upper pole mass, was converted to open nonischemic PN due to dense upper pole adhesions and nonprogression due to a prior history of multiple intra-abdominal procedures and radiation. There were no conversions to ischemic partial nephrectomy, open surgery, or radical nephrectomy.

Table 1 demonstrates demographics and tumor characteristics. Mean followup was 16.3 ± 10.5 months and was significantly longer for multiport LPN (18.8 ± 10.8) than for LESS-PN (9.4±2.6, P = .004). Mean age was 57.9±12.7 years. 31 (51.7%) were male, and 29 (48.3%) were female. Mean BMI was 28.4 ± 0.5 kg/m². 66.7% (40) were Caucasian and 33.3% (20) were other. Mean tumor size was 2.35 ± 1.30 cm. No significant difference was found between MPL and LESS-PN groups with respect to age, gender/race distribution, BMI, or tumor size.
### Table 1: Patient demographics and tumor characteristics.

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Multiport LPN</th>
<th>LESS-PN</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean f/u (months)</td>
<td>16.3 ± 10.5</td>
<td>18.8 ± 10.8</td>
<td>9.4 ± 2.6</td>
<td>.004</td>
</tr>
<tr>
<td>Mean age (yrs.)</td>
<td>57.9 ± 12.7</td>
<td>57.4 ± 13.3</td>
<td>59.3 ± 11.7</td>
<td>.627</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td>.547</td>
</tr>
<tr>
<td>Male</td>
<td>31 (51.7%)</td>
<td>25 (54.3%)</td>
<td>6 (42.9%)</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>29 (48.3%)</td>
<td>21 (46.7%)</td>
<td>8 (57.1%)</td>
<td></td>
</tr>
<tr>
<td>Mean BMI (Kg/m²)</td>
<td>28.4 ± 0.5</td>
<td>28.0 ± 4.8</td>
<td>28.7 ± 5.5</td>
<td>.737</td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td>.195</td>
</tr>
<tr>
<td>Caucasian</td>
<td>40 (66.7%)</td>
<td>33 (71.6%)</td>
<td>7 (50%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>20 (33.3%)</td>
<td>13 (28.3%)</td>
<td>7 (50%)</td>
<td></td>
</tr>
<tr>
<td>Laterality</td>
<td></td>
<td></td>
<td></td>
<td>.770</td>
</tr>
<tr>
<td>Right</td>
<td>28 (46.7%)</td>
<td>22 (47.8%)</td>
<td>6 (42.9%)</td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>32 (52.3%)</td>
<td>24 (52.2%)</td>
<td>8 (57.1%)</td>
<td></td>
</tr>
<tr>
<td>Tumor location</td>
<td></td>
<td></td>
<td></td>
<td>.043</td>
</tr>
<tr>
<td>Upper pole</td>
<td>13 (21.7%)</td>
<td>10 (21.8%)</td>
<td>3 (21.4%)</td>
<td></td>
</tr>
<tr>
<td>Mid-pole</td>
<td>20 (33.3%)</td>
<td>14 (30.4%)</td>
<td>6 (42.9%)</td>
<td></td>
</tr>
<tr>
<td>Lower pole</td>
<td>27 (45.0%)</td>
<td>22 (47.8%)</td>
<td>5 (35.7%)</td>
<td></td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td>2.35 ± 1.30</td>
<td>2.47 ± 1.38</td>
<td>1.95 ± 0.92</td>
<td>.189</td>
</tr>
</tbody>
</table>

### Table 2: Perioperative parameters, outcomes, and complications.

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Multiport LPN</th>
<th>LESS-PN</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean OR time (min)</td>
<td>164.0 ± 48.8</td>
<td>159.9 ± 52.1</td>
<td>177.4 ± 34.0</td>
<td>.242</td>
</tr>
<tr>
<td>Mean EBL (mL)</td>
<td>131.4 ± 98.1</td>
<td>126.6 ± 94.7</td>
<td>148.1 ± 112</td>
<td>.491</td>
</tr>
<tr>
<td>Collecting system entry</td>
<td>17 (28.3%)</td>
<td>11 (23.9%)</td>
<td>6 (42.9%)</td>
<td>.190</td>
</tr>
<tr>
<td>LOS (days)</td>
<td>2.60 ± 1.17</td>
<td>2.61 ± 1.23</td>
<td>2.57 ± 0.94</td>
<td>.917</td>
</tr>
<tr>
<td>Preoperative serum creatinine (mg/dL)</td>
<td>1.02 ± 0.41</td>
<td>1.06 ± 0.43</td>
<td>0.89 ± 0.33</td>
<td>.187</td>
</tr>
<tr>
<td>Postoperative serum creatinine (mg/dL)</td>
<td>1.07 ± 0.45</td>
<td>1.10 ± 0.47</td>
<td>0.97 ± 0.35</td>
<td>.340</td>
</tr>
<tr>
<td>Preoperative eGFR (mL/min/1.73 m²)</td>
<td>81.4 ± 26.9</td>
<td>79.4 ± 27.2</td>
<td>88.1 ± 26.0</td>
<td>.293</td>
</tr>
<tr>
<td>Postoperative eGFR (mL/min/1.73 m²)</td>
<td>77.7 ± 29.6</td>
<td>77.4 ± 31.0</td>
<td>78.5 ± 25.1</td>
<td>.905</td>
</tr>
<tr>
<td>Final pathology</td>
<td></td>
<td></td>
<td></td>
<td>.759</td>
</tr>
<tr>
<td>RCC</td>
<td>34 (56.7%)</td>
<td>27 (58.7%)</td>
<td>7 (50%)</td>
<td></td>
</tr>
<tr>
<td>Benign histology</td>
<td>26 (43.3%)</td>
<td>19 (41.3%)</td>
<td>7 (50%)</td>
<td></td>
</tr>
<tr>
<td>Negative margins</td>
<td>60 (100%)</td>
<td>46 (100%)</td>
<td>14 (100%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Complications</td>
<td>12 (20%)</td>
<td>9 (10.5%)</td>
<td>3 (21.4%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Urine leak</td>
<td>3 (5%)</td>
<td>2 (4.3%)</td>
<td>1 (7.1%)</td>
<td>.556</td>
</tr>
</tbody>
</table>

Table 2 shows perioperative parameters, outcomes, and complications. Mean operative time was 164.0 ± 48.8 minutes, and mean estimated blood loss was 131.4 ± 98.1 mL. Collecting system entry was made in 17/60 (28.3%). Mean hospital length of stay was 2.60 ± 1.17 days. Final pathology was renal cell carcinoma in 34 (56.7%) and Benign histology in 26 (43.3%) (oncocytoma (5), AML (13), other (8)). All had negative surgical margins. Preoperative serum creatinine (mg/dL) and creatinine at the time of last followup were 1.02 ± 0.41 and 1.07 ± 0.45 (\(P = .471\)). Preoperative eGFR (mL/min/1.73 m²) and eGFR at the time of the last followup were 81.4 ± 26.9 and 77.7 ± 29.6 (\(P = .471\)). There were no significant differences between multiport and LESS-PN with respect to mean operative time, EBL, collecting system entry,
length of stay, preoperative/postoperative creatinine and eGFR, and pathological distribution. At the last followup, all patients were alive and disease-free.

There were 12 complications in 12 patients (20%) in our series. 1 (1.7%) patient developed clot obstruction which required stent placement on postoperative day 2. 3 (5%) patients developed urine leaks which resolved with conservative management (two were early leaks managed with Jackson-Pratt drain continuing for 1 and 2 weeks, respectively. 1 patient developed a delayed urinary leak treated with percutaneous drain placement). All leaks were resolved with conservative management. 3 patients (5%) developed postoperative ileus managed conservatively. 1 patient (1.7%) developed each of the following: atrial fibrillation, cystitis, diverticulitis, pneumonia, and pneumothorax. 1 patient received a platelet and blood transfusion, who had a history of preoperative anemia and idiopathic thrombocytopenic purpura. There were no significant differences between the groups with respect to complication and leak rates.

4. Discussion

By duplicating principles of open partial nephrectomy, laparoscopic partial nephrectomy has demonstrated equivalence in oncological outcomes [8, 9, 23] while providing the benefits of minimally invasive surgery such as improved cosmesis, lower narcotic requirements, shorter hospital stays, and more rapid return to normal activities [24, 25]. Adoption of laparoscopic partial nephrectomy, however, continues to be hampered by concerns regarding the achievement of reliable hemostasis [26] and prolonged warm ischemia time and its possible consequences as regards long-term renal function [8, 9, 27, 28].

Interest in reducing or eliminating ischemic renal occlusion has spurred the development of a variety of strategies including sutureless renorrhaphy [29, 30], superselective embolization of segmental vessels [31], and energy-based nonischemic renal resection utilizing laser [32, 33], microwave tissue ablation [34], and monopolar radiofrequency devices [35, 36]. Partial nephrectomy utilizing bipolar radiofrequency device was first investigated by Pareek et al. [37] in a porcine model. In humans, Andonian et al. [38] were the first to report success in humans with renal masses smaller than 2 cm utilizing the Habib 4X. White et al. [15] reported a randomized controlled trial utilizing the Habib 4X in open partial nephrectomy versus ischemic open partial nephrectomy, reporting a significant decrease in blood loss and operative time for tumors with mean size of 3.3 cm. Zeltser et al. [39] used the laparoscopic Habib 4X in a porcine model with good results, and recently, Nadler et al. [20] reported their clinical experience in 16 patients who underwent a hybrid laparoscopic and robotic-assisted laparoscopic partial nephrectomy with the Habib 4X. They noted a median blood loss of 125 mL, median operative time of 435 minutes, mean hospital stay of 2.6 days, and with good renal functional preservation (preoperative/postoperative serum creatinine of 1.03/1.10). Importantly, all patients had negative margins, and none were converted to ischemic or open technique. Our multicenter experience, utilizing pure laparoscopy, demonstrates similar outcomes with respect to estimated blood loss (131 mL), hospital stay (2.60 days), and preservation of renal function (preoperative/postoperative serum creatinine 1.02/1.07, Table 2) to those achieved by Nadler et al. [20] with decreased operative time (164 minutes) and with the cost savings of using a purely laparoscopic platform [40].

Warm ischemia time is a major road block in performing laparoscopic partial nephrectomy [27]. Indeed, while refinement of technique and emerging reports on the feasibility of robotically assisted laparoscopy for nephron sparing surgery, concern continues regarding potentially longer warm ischemia times for minimally invasive surgery. On the other hand, concerns have been raised regarding energy-based modalities and potential limitations with respect to the assessment of margins status as well as efficacy of collecting system closure and reconstruction. By eliminating warm ischemia and facilitating complex reconstruction with robotically assisted laparoscopy, Nadler et al. [20] have pointed the way in expanding the range of utilization of nephron sparing surgery. Indeed, our experience with 17/60 (28.3%) of patients/tumors, Table 2) collecting system entries and
sutured renorrhaphy (Figure 2) confirms that the utilization of nonischemic technique is ideally suited for a minimally invasive surgery as elimination of ischemia time will not only allay concerns about the prolongation of ischemia time and its deleterious effects, but also permit complex reconstruction and therefore ultimately enhance the adoption of minimally invasive nephron sparing surgery for a wider variety of tumors. Our urinary leak rate of 5% (3 patients), all of whom resolved with conservative measures, is consistent with rates reported in large series of laparoscopic partial nephrectomy [8, 20–22]. Furthermore, as demonstrated by our results, adhering to a 1 cm margin outside the tumor permitted the Habib 4X, a four-pronged device (prongs are set 8 mm apart) with minimal lateral coagulation spread, to achieve a zone of coagulation that was away from the tumor. Indeed, our 0% negative pathologic margins bear this out (Table 2).

Indeed, in addition to a comparable leak rate, our outcomes as regards to blood loss, operative time, margin positivity, and renal functional preservation compare very favorably with large published multicenter studies (Table 3) [8, 20–22]. These data demonstrate that nonischemic laparoscopic partial nephrectomy utilizing the Habib 4X is not only feasible but has a similar safety profile to established techniques and does not compromise oncological outcomes with respect to margin positivity.

LESS-PN allows for the extraction of the enhancing renal lesion, a definitive histologic confirmation with excellent preservation of renal function in this series. In a recent publication, Kaouk and Goel utilized a nonischemic technique to perform LESS-PN. After PN, these authors achieved hemostasis using ABC, Surgicel and a variety of surgical adhesives; however, due to inability to achieve adequate hemostasis in one case, they had to convert to multiport laparoscopy [12]. Our experience with 14 LESS-PN not only confirms the feasibility of this procedure, but in a well-matched cohort (Table 1) demonstrates similar outcomes (Table 2) to our multiport LPN group. Indeed, the Habib 4X, which easily fits through the 12 mm laparoscopic port, was a key facilitator of the LESS-PN approach, by allowing controlled excision of the mass through a precreated hemostatic plane around the tumor, and therefore minimizing instrument clashing and potential loss of hemostatic control in a crucial portion of the case. Furthermore, by creating a hemostatic field, we were able to proceed with the renorrhaphy in a meticulous manner and be able to surmount the limitations of the LESS platform (instrument clashing, triangulation) in an environment without the pressure of ischemic time. While further investigation and comparison is necessary, this preliminary series demonstrates that LESS-PN is safe and technically feasible method for performing complex renal surgery while maintaining strict adherence to oncologic principles. Our encouraging results are the first reported comparison between multiport and LESS-PN. Further studies, in addition to a comparison of quality-of-life outcomes, are necessary to delineate what, if any specific advantages, may lie with the LESS approach.

Our data is limited by its retrospective nature, limited numbers, and short-term follow-up. Nonetheless, we are encouraged by the preliminary findings of our experience. Further prospective comparison with ischemic partial nephrectomy with longer-term outcomes is requisite.

## 5. Conclusion

Initial experience demonstrates that nonischemic L-NSS utilizing Habib 4X is safe and efficacious, with excellent short-term preservation of renal function. In addition to longer-term followup, direct prospective comparison to ischemic NSS is requisite to confirm the renal functional preservation and oncological efficacy of this technique.

### Conflict of Interests

The authors declare that there is no Conflict of Interests.

### References


[3] R. H. Thompson, S. A. Boorjian, C. M. Lohse et al., "Radical nephrectomy for pT1a renal masses may be associated with


Submit your manuscripts at http://www.hindawi.com